特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

リキッドバイオプシーの世界市場:市場動向・成長予測・競合分析

Liquid Biopsy Market Report: Trends, Forecast, and Competitive Analysis

発行 Lucintel - Semi-Custom Reports 商品コード 945068
出版日 ページ情報 英文
納期: 約3~5週間
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。

【セミカスタムオーダー型の調査レポート】
当レポートは、目次内の調査項目について *追加/変更ご要望を反映させる事も可能です。
ご注文を承った時点からLucintel社データベースより最新のデータを抽出・分析・編集を行うため、納品には約3~5週間程度を要します。
* ご要望が無い場合は目次通りの内容構成にて作成となります。
* ご要望項目の分量によりましては追加費用が発生する場合がございます。

リキッドバイオプシーの世界市場:市場動向・成長予測・競合分析 Liquid Biopsy Market Report: Trends, Forecast, and Competitive Analysis
出版日: 2020年06月01日 ページ情報: 英文
概要

世界のリキッドバイオプシーの市場は予測期間中23%のCAGRで成長すると予測されています。癌の有病率の増加、非侵襲的処置が好まれる傾向、個別化医療への関心の高まり、R&Dなどの要因が同地域の成長を推進しています。

当レポートでは、世界のリキッドバイオプシーの市場を調査し、市場および技術の概要、サプライチェーン 、市場への各種影響因子の分析、市場規模の推移・予測、製品区分・血中バイオマーカータイプ・臨床用途・用途・エンドユーザー・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 市場の背景と分類

  • イントロダクション・背景・分類
  • サプライチェーン
  • 産業推進要因・課題

第3章 市場動向・予測分析

  • マクロ経済の動向・予測
  • 世界のリキッドバイオプシー市場:動向・予測
  • 世界のリキッドバイオプシー市場:製品別
    • アッセイキット
    • 機器
    • サービス
  • 世界のリキッドバイオプシー市場:血中バイオマーカー別
    • 循環腫瘍細胞(CTC)
    • 循環腫瘍DNA(ctDNA)
    • 無細胞DNA(cfDNA)
    • 細胞外小胞(EV)
    • その他
  • 世界のリキッドバイオプシー市場:臨床用途別
    • 早期癌スクリーニング
    • 療法の選択
    • 治療モニタリング
    • 再発モニタリング
  • 世界のリキッドバイオプシー市場:用途別
    • 腫瘍学
    • 肺癌
    • 乳癌
    • 大腸癌
    • 前立腺癌
    • 肝臓癌
    • その他の癌
    • 非癌
  • 世界のリキッドバイオプシー市場:エンドユーザー別
    • リファレンスラボ
    • 病院・医師ラボ
    • 学術・研究センター
    • その他

第4章 市場動向・予測分析:地域・主要国別

  • 地域別市場
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域
    • 製品別
    • 血中バイオマーカー別
    • 臨床用途別
    • 用途別
    • エンドユーザー別
    • 国別

第5章 競合分析

  • 製品ポートフォリオ分析
  • 市場シェア分析
  • 運用統合
  • 地域的リーチ
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会の分析
  • 新興動向
  • 戦略的分析

第7章 主要企業のプロファイル

  • Biocept
  • Qiagen
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Menarini-Silicon Biosystems
  • Trovagene
  • Guardant Health
  • Mdxhealth
  • Enomic Health
目次

The future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid biopsy market is expected to grow with a CAGR of 23% from 2019 to 2024. The major growth drivers for this market are increasing prevalence of cancer, increasing preference for noninvasive procedures, rising emphasis on personalized medicine, and availability of funding for liquid biopsy research and development.

A report of more than 150 pages is developed to help in your business decisions. Sample figures with some insights are shown below. To learn the scope of, benefits, companies researched and other details of liquid biopsy market report download the report brochure.

The study includes the liquid biopsy market size and forecast for the global liquid biopsy market through 2024, segmented by product, circulating biomarker, clinical application, application, end use, and region as follows:

By Product [$M shipment analysis for 2013 - 2024]:

  • Assays Kits
  • Instruments
  • Services

By Circulating Biomarker [$M shipment analysis for 2013 - 2024]:

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers

By Clinical Application [$M shipment analysis for 2013 - 2024]:

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring Orthopedics

By Application [$M shipment analysis for 2013 - 2024]:

  • Oncology
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Other Cancers
  • Non-Cancer Application

By End Use [$M shipment analysis for 2013 - 2024]:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Region [$M shipment analysis for 2013 - 2024]:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
  • ROW
    • Brazil

Some of the liquid biopsy companies profiled in this report include Biocept, Qiagen, Roche Diagnostics, Bio-Rad Laboratories, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina.

Some of the features of "Global Liquid Biopsy Market 2019-2024: Trends, Forecast, and Opportunity Analysis" include:

  • Market size estimates:Global liquid biopsy market size estimation in terms of value ($M) shipment.
  • Trend and forecast analysis:Market trend (2013-2018) and forecast (2019-2024) by segments and region.
  • Segmentation analysis:Global market size by product, circulating biomaker, clinical application, application, end use, and region.
  • Regional analysis:Global liquid biopsy market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
  • Growth opportunities:Analysis on growth opportunities in different applications and regions for liquid biopsy in the global liquid biopsy market.
  • Strategic analysis:This includes M&A, new product development, and competitive landscape for, liquid biopsy in the global liquid biopsy market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising potential, high-growth opportunities for the global liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers ( include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers.)), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics), application (oncology, lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, other cancers (bladder cancer, pancreatic cancer, brain and nervous system cancer, ovarian cancer and melanoma), non-cancer application), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users), and region (North America, Europe, Asia-Pacific, and ROW)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which regions will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the liquid biopsy market?
  • Q.5. What are the business risks and threats to the liquid biopsy market?
  • Q.6. What are emerging trends in this liquid biopsy market and the reasons behind them?
  • Q.7. What are some changing demands of customers in the liquid biopsy market?
  • Q.8. What are the new developments in the liquid biopsy market? Which companies are leading these developments?
  • Q.9. Who are the major players in this liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?
  • Q.10. What are some of the competitive products and processes in this liquid biopsy area and how big of a threat do they pose for loss of market share via material or product substitution?
  • Q.11. What M & A activities have taken place in the last 5 years in liquid biopsy market?

1. Executive Summary

2. Market Background and Classifications

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

  • 3.1: Macroeconomic Trends and Forecast
  • 3.2: Global Liquid Biopsy Market: Trends and Forecast
  • 3.3: Global Liquid Biopsy Market by Product
    • 3.3.1: Assays Kits
    • 3.3.2: Instruments
    • 3.3.3: Services
  • 3.4: Global Liquid Biopsy Market by Circulating Biomarker
    • 3.4.1: Circulating Tumor Cells (CTCs)
    • 3.4.2: Circulating Tumor DNA (ctDNA)
    • 3.4.3: Cell-Free DNA (cfDNA)
    • 3.4.4: Extracellular Vesicles (EVs)
    • 3.4.5: Other Circulating Biomarkers
  • 3.5: Global Liquid Biopsy Market by Clinical Application
    • 3.5.1: Early Cancer Screening
    • 3.5.2: Therapy Selection
    • 3.5.3: Treatment Monitoring
    • 3.5.4: Recurrence Monitoring Orthopedics
  • 3.6: Global Liquid Biopsy Market by Application
    • 3.6.1: Oncology
    • 3.6.2: Lung Cancer
    • 3.6.3: Breast Cancer
    • 3.6.4: Colorectal Cancer
    • 3.6.5: Prostate Cancer
    • 3.6.6: Liver Cancer
    • 3.6.7: Other Cancers
    • 3.6.8: Non-Cancer
  • 3.7: Global Liquid Biopsy Market by End Use
    • 3.7.1: Reference Laboratories
    • 3.7.2: Hospitals and Physician Laboratories
    • 3.7.3: Academic and Research Centers
    • 3.7.4: Other End Users

4. Market Trends and Forecast Analysis by Region

  • 4.1: Global Liquid Biopsy Market by Region
  • 4.2: North American Liquid Biopsy Market
    • 4.2.1: Market by Product: Assays Kits, Instruments, and Services
    • 4.2.2: Market by Circulating Biomarker: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers
    • 4.2.3: Market by Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring Orthopedics
    • 4.2.4: Market by Application: Oncology, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Other Cancers, and Non-Cancer
    • 4.2.5: Market by End Use: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers, and Other End Users
  • 4.3: European Liquid Biopsy Market
    • 4.3.1: Market by Product: Assays Kits, Instruments, and Services
    • 4.3.2: Market by Circulating Biomarker: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers
    • 4.3.3: Market by Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring Orthopedics
    • 4.3.4: Market by Application: Oncology, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Other Cancers, and Non-Cancer
    • 4.3.5: Market by End Use: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers, and Other End Users
  • 4.4: APAC Liquid Biopsy Market
    • 4.4.1: Market by Product: Assays Kits, Instruments, and Services
    • 4.4.2: Market by Circulating Biomarker: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers
    • 4.4.3: Market by Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring Orthopedics
    • 4.4.4: Market by Application: Oncology, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Other Cancers, and Non-Cancer
    • 4.4.5: Market by End Use: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers, and Other End Users
  • 4.5: ROW Liquid Biopsy Market
    • 4.5.1: Market by Product: Assays Kits, Instruments, and Services
    • 4.5.2: Market by Circulating Biomarker: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers
    • 4.5.3: Market by Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring Orthopedics
    • 4.5.4: Market by Application: Oncology, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Other Cancers, and Non-Cancer
    • 4.5.5: Market by End Use: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers, and Other End Users

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Market Share Analysis
  • 5.3: Operational Integration
  • 5.4: Geographical Reach
  • 5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for Global Market by Product
    • 6.1.2: Growth Opportunities for Global Market by Circulating Biomarker
    • 6.1.3: Growth Opportunities for Global Liquid Biopsy Market by Clinical Application
    • 6.1.4: Growth Opportunities for Global Liquid Biopsy Market by Application
    • 6.1.5: Growth Opportunities for Global Liquid Biopsy Market by End Use
    • 6.1.6: Growth Opportunities for Global Liquid Biopsy Market by Region
  • 6.2: Emerging Trends in Global Liquid Biopsy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of Global Liquid Biopsy Market
    • 6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Liquid Biopsy Market

7. Company Profiles of Leading Players

  • 7.1: Biocept
  • 7.2: Qiagen
  • 7.3: Roche Diagnostics
  • 7.4: Bio-Rad Laboratories
  • 7.5: Menarini-Silicon Biosystems
  • 7.6: Trovagene
  • 7.7: Guardant Health
  • 7.8: Mdxhealth
  • 7.9: Enomic Health